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The transplantation of islets of Langerhans has been successfully applied to the treatment 
of insulin-dependent diabetes. However, a shortage of human donors is the hardest 
obstacle to overcome. We aimed to develop a bioartificial pancreas that can realize xeno-
islet transplantation. The islets were encapsulated in agarose microbeads carrying the 
soluble domain of human complement receptor 1 (sCR1), which is an effective inhibitor 
of the classical and alternative complement activation pathways. When naked rat islets 
were cultured in rabbit serum, large amounts of insulin leaked from the damaged islets 
over the course of a few days incubation, but no damaged cells were observed among 
islets in sCR1-agarose microbeads cultured in rabbit serum for 4 days. Although low 
levels of insulin were detected in the rabbit serum, the insulin did not leak from damaged 
β-cells, it was physiological insulin secreted by the β-cells.  
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The transplantation of islets of Langerhans has been successfully applied to the treatment 
of patients with insulin-dependent diabetes mellitus (type 1 diabetes). However, several 
obstacles still remain, such as a shortage of human donors, low efficacy of islet isolation, 
and side effects of immunosuppressive drugs, among which the shortage of human 
donors is the most difficult to overcome. Recently, Hering et al. [1] reported that 
normoglycemia can be maintained for more than 100 days in STZ-induced diabetic 
cynomolgus macaques after intraportal transplantation of adult porcine islets. The study 
suggested opening up the use of pig islet xenograft transplantation to human patients. 
However, rationalizing the use of a large dose of immuno-suppressive drugs, which are 
required to control graft rejection in xenotransplantation, is difficult. The side effects of 
immunosuppressive therapy are expected to exceed the merits of islet transplantation.  
The transplantation of islets enclosed in a semi-permeable membrane as a bioartificial 
pancreas has been studied as a method of islet transplantation free from 
immunosuppressive therapy. Islets can survive and control glucose metabolism for a long 
period of time in a host without immunosuppressive therapy because islets are isolated 
from the host immune system by a semi-permeable membrane. Various types of 
bioartificial pancreas have been proposed and developed, including islets 
microencapsulated within an alginate/poly(L-lysine) polyion complex membrane [2] or 
agarose hydrogel [3], or macroencapsulated by porous membranes [4-6] or living cells 
[7,8]. Our group previously developed a microcapsule-type bioartificial pancreas using 
agarose hydrogel and demonstrated its efficacy in allotransplantation models [3, 9-11].  




































































rejection. A combination of islet microencapsulation and mild immunosuppressive 
therapy could achieve xeno-islet transplantation [12].  
In the present study, agarose hydrogel carrying a complement regulatory protein, the 
soluble form of complement-receptor type 1 (sCR1-agarose), was prepared and applied to 
encapsulate rat islets. Complement receptor type 1 (CR1) has been reported to be an 
effective inhibitor of the classical and alternative complement activation pathways [13-
20].  The protective effect of sCR1-agarose on xeno-islets against antibody-complement-
dependent destruction was examined by incubating the microencapsulated islets in rabbit 
serum. 
 
2. Material and methods 
2.1. Materials 
A Chinese hamster ovary (CHO35.6) cell line expressing sCR1 (CRL-10052
TM
) [16] was 
obtained from American Type Culture Collection (ATCC; Manassas, VA, USA). Alexa 
488-labeled goat anti-mouse antibody and mouse anti-human sCR1 monoclonal antibody 
(J3D3) were purchased from Invitrogen (Carlsbad, CA, USA) and Beckman Coulter (CA, 
USA), respectively. 2-Iminothiolane hydrochloride (Traut’s reagent) was purchased from 
MP Biomedicals (Illkirch, France). The N-(p-maleimidophenyl) isocyanate (PMPI) was 
purchased from Thermo Fisher Scientific (Rockford, IL., USA). Agarose (Taiyo Agarose, 
AG LT-600) was obtained from Shimizu shokuhin KK (Shimizu, Japan), and paraffin oil 
(107162) was purchased from Merck (NJ, USA). Enzyme-linked immunosorbent assay 
(ELISA) kits for the insulin assay and CH50 autokit were purchased from Shibayagi 



































































purchased from Nitta Gelatin (Osaka, Japan). The sources of other chemicals and culture 
media are listed in the supplemental information.  
 
2.2. sCR1 purification  
Human sCR1 was purified from the culture medium of CHO cells expressing sCR1 as 
previously described [21]. Briefly, the cells were first cultured in α-MEM medium 
supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml 
streptomycin, and 500 nM methotrexate (MTX). After the cells reached confluence, they 
were washed three times with phosphate buffered saline (PBS) and cultured in serum-free 
ASF104 medium (Ajinomoto Co. Inc., Tokyo, Japan) supplemented with 500 nM MTX 
for an additional 2 days. The culture medium was collected and centrifuged at 1000 rpm 
for 5 min, the supernatant filtered through a membrane filter (ϕ:0.45 μm), and stored at 
4°C before purification.  
sCR1 was collected from the CHO culture medium by affinity column chromatography 
using a heparin sepharose 6B column. A 500 ml sample of the medium was loaded onto 
the heparin column and contaminants washed out using a 10 mM NaH2PO4 (pH 7.0) 
buffer solution. Bound sCR1 was eluted with an elution buffer composed of 10 mM 
NaH2PO4 and 1 M NaCl (pH 7.0). The protein concentration of the eluent was 
determined using a micro BCA protein assay kit. The collected sCR1 was subjected to 
SDS-PAGE analysis with coomassie brilliant blue (CBB) staining. The sCR1 solution 
was diluted with PBS and divided into 100 μl aliquots in 50 tubes and stored at -20°C 
until assayed. The sCR1 activity in the solution was evaluated with the CH50 assay using 



































































slight modifications [22]. Briefly, 250 μl hapten-liposome solution was added to a 
mixture of 9 μl of normal human serum (NHS) and 1 μl sCR1 solution (25 to 300 μg/ml) 
in PBS. The solution was incubated at 37°C. After 5 min, 125 μl of an antibody–substrate 
mixture was added to the solution. After incubating at 37°C for 4.6 min, absorbance was 
measured at 340 nm. The complement activation level (CH50 value) of the NHS-sCR1 
mixture was determined from the absorbance using a standard curve. In the case of rabbit 
serum, a serum-sCR1 mixture was prepared by mixing 27 μl rabbit serum and 3 μl sCR1 
solution in PBS (25 to 300 μg/ml). The CH50 assay was conducted as described for NHS. 
 
2.3. Chemical modification of sCR1 and agarose  
sCR1 was immobilized on the agarose hydrogel as shown in Scheme 1. First, sCR1 was 
thiolated using Traut’s reagent by mixing 1 ml of 2 mg/ml sCR1 solution in PBS with 10, 
20, or 50 μl of 10 mg/ml Traut‘s reagent solution in PBS by agitating for 1 h at room 
temperature. Thiolated sCR1 (sCR1-SH) was purified using a sephadex G25 column (GE 
Healthcare, Buckinghamshire, UK). The number of thiol groups introduced to the sCR1 
molecule was determined using Ellman’s assay. The complement inhibition function of 
sCR1 before and after thiolation was determined by the CH50 assay.  
The hydroxyl groups of agarose were modified to maleimide groups using PMPI as 
follows. PMPI (2 to 5 mg) was added to an agarose solution in dry DMSO (100 mg 
agarose in 5 ml DMSO) and stirred at room temperature under dark condition overnight. 
The modified agarose (Mal-agarose) was collected by pouring the reaction mixture into 
acetone. After decanting, the precipitated product was washed with acetone twice and 




































































2.4. Protective effect of sCR1 immobilized on agarose hydrogel 
Hapten-liposomes encapsulated in 2.5% agarose microbeads (LAMs) were utilized to 
examine the protective effect of sCR1 immobilized on agarose. Mal-agarose (150 mg) 
was dissolved in 3 ml PBS in a glass centrifugal tube using a microwave oven to prepare 
a 5% agarose solution. The agarose solution was left at 40°C for 7 min. The hapten-
liposome suspension, which was supplied as a component of the CH50 assay kit and kept 
at 40°C, was added to an equal volume (3 ml) of the 5% agarose solution and mixed well. 
Pre-warmed liquid paraffin (15 ml, 40°C) was added to the glass tube, and the tube was 
vigorously agitated on ice for 3 min to induce gelation of the agarose microdroplets. Cold 
PBS (15 ml) was added to the glass tube and the suspension was centrifuged at 2000 rpm 
for 5 min at 4°C. The paraffin oil and supernatant were removed and the microbeads 
washed twice with PBS. The volume of the microbead suspension was adjusted to 500 μl 
after removing the supernatant. For immobilization of sCR1 on the agarose microbeads, 
800 μg of sCR1-SH in 1 ml PBS was added to 500 μl of the microencapsulated liposome 
suspension, and the reaction mixture was incubated at 37°C for 2 h with gentle shaking 
every 30 min. After 2 hours, the microbeads were suspended in PBS and centrifuged at 
2000 rpm for 5 min at 4°C. This procedure was repeated 5 times to remove free sCR1-
SH. As a control, a cysteine solution (1 mM), instead of the sCR1 solution, was added to 
agarose solution. The LAMs treated with or without sCR1 were stored in 10 ml PBS 
overnight to remove unreacted sCR1 and cysteine. 
The CH50 assay using the CH50 autokit was modified to evaluate the inhibitory effect of 



































































immobilized LAMs (200 μl) were mixed with 1 ml of 5-times diluted NHS in veronal 
buffer and was incubated at 37°C for 5 min. Then, 125 μl of the substrate solution was 
added to the mixture and kept at 37°C. Two hundred microliters of supernatant was 
collected at 25, 45, and 65 min during the incubation and the absorbance at 340 nm 
determined. The percentage of lysis in the LAMs was calculated from the absorbance 
value of completely lysed LAMs, which were incubated for 3 h in serum.  
The amount of sCR1 immobilized to the agarose microbeads was determined by the 
micro BCA assay using microbeads without encapsulation of the hapten-liposome.  
 
2.5. Isolation and microencapsulation of islets  
Islets were isolated from male, 8-week-old ACI/N rats by the ductal injection of a 
collagenase solution [23]. Briefly, a rat was anesthetized by intraperitoneal injection of 
Nembutal (pentobarbital, 75 mg/kg). Approximately 10 ml of collagenase solution (0.5 
mg/ml) was carefully injected through the common bile duct to the pancreas to distend 
the tissue. The pancreas was removed and kept at 37°C for 19 min to digest the 
pancreatic tissue. RPMI-1640 (5 ml) containing 10% FBS was added to the sample and 
the tissue was pipetted vigorously to release islets from the exocrine tissues. The 
disintegrated tissue was washed twice with HBSS and the supernatant removed after 
centrifugation. The tissue was suspended  in 5 m Ficoll/Conray solution (density: 1.1 
g/ml) and transferred to a test tube. Ficoll/Conray solutions with a density of 1.075 g/ml 
and 1.050 g/ml (3 ml and 2 ml, respectively) were sequentially layered on the suspension 
to make a discontinuous density gradient. The test tube was centrifuged at 2500 rpm for 8 



































































After washing the islets, they were transferred to culture medium (RPMI-1640) 
supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin and 
cultured for 2 days before encapsulation with agarose microbeads. 
Islets were encapsulated in sCR1-agarose microbeads using the same method as hapten-
liposomes detailed above. Microencapsulated islets were cultured in RPMI1640 
supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C 
in 5% CO2. The sCR1 immobilized in microbeads was visualized by immunostaining. 
After 2 days of culture, microbeads containing islets were kept in culture medium 
containing anti-human sCR1 monoclonal antibody (1 μg/ml, J3D3 mouse antibody) for 6 
h at 37°C. The islets were washed and incubated in antibody-free medium for 1 day to 
complete remove unbound antibodies. The sCR1 in the microbeads was visualized by 
incubation in culture medium containing Alexa 488-labeled anti-mouse antibody (1 
μg/ml, goat) for 6 h at 37°C, and then the Alexa 488-labeled antibody was extensively 
removed by culturing the microencapsulated islets in antibody-free medium for 24 h.  
The agarose microbeads were observed by confocal laser scanning microscopy 
(Fluoview, FV500, Olympus Optical Co. Ltd., Tokyo, Japan). 
The ability of the microencapsulated islets to release insulin was examined by the static 
glucose-stimulated test [24]. Briefly, 50 microencapsulated islets were sequentially 
incubated in Krebs-Ringer solutions with glucose concentrations of 0.1 g/dl, 0.3 g/dl, and 
0.1 g/dl for 1 h each at 37°C. At the end of each incubation, supernatants were collected 




































































2.6. Inhibition of the complement-dependent destruction of islets by sCR1 immobilized on 
agarose 
Rabbit serum was used to examine the sCR1 protection of rat islets from complement-
dependent destruction. Twenty naked islets and 20 islets encapsulated in agarose 
microbeads with or without sCR1 were cultured in 100% normal rabbit serum at 37°C. 
Serum was collected every 24 h and replaced by fresh serum after three washes with 
HBSS. The insulin contents of the collected sera were determined by ELISA. Islet 
morphology was observed by phase contrast microscopy (IX71, Olympus Optical Co. 
Ltd., Tokyo, Japan).  
 
2.7. Statistical analysis 
Comparisons between two groups were performed using the Student’s t-test. P <0.05 was 






































































3.1. Isolation and function of CHO sCR1 
The SDS-PAGE of fresh ASF104 medium, conditioned CHO cell medium, and purified 
sCR1 is shown in Fig. 1A. A band appeared in the conditioned medium at roughly 250 
kDa was assigned to sCR1 (Mw: 220 kDa). Bands at 80 kDa in the fresh and conditioned 
medium were assigned to transferin. After sCR1 was purified using a heparin column, 
most contaminants were removed (Fig. 1A, line c). Approximately 10-20 μg of sCR1 was 
isolated from 1 ml of culture medium.  
The inhibitory effect of sCR1 on complement activation was determined with the CH50 
assay. The CH50 value decreased with increasing sCR1 concentrations (Fig. 1B), 
indicating that sCR1 isolated from the conditioned CHO cell medium can effectively 
inhibit complement activation.  
In xenotransplantation, complement regulatory proteins, such as decay accelerating 
factors and CD46, are used to impair the assembly of the membrane attack complex. In 
some donor and recipient combinations, however, the inhibitory properties of these 
molecules are not effective due to species restriction [25]. We examined the inhibitory 
effects of human sCR1 on complement activation in rabbit serum. With the addition of 
sCR1 to the serum, the increased absorbance at 340 nm remained low (Fig. 1C). This 
finding indicates that sCR1 can also effectively inhibit complement activation in rabbit 
serum. 
 



































































The number of thiol groups introduced on sCR1 increased with increasing Traut’s reagent 
concentration (S-Fig. 1). The CH50 value of NHS was 38.9 U/ml. When naïve sCR1 was 
added to NHS at 2 μg/ml, the CH50 value decreased to 24.6 U/ml. When sCR1-SH 
carrying 4.6, 7.6, or 10.8 thiol groups per molecule were added to NHS at 0.26 μg/ml, the 
CH50 value decreased to 26.46, 26.18, and 28.09 U/ml, respectively (Fig. 2). Although 
the inhibitory function of sCR1 tended to decrease with an increasing number of 
introduced thiol groups, it did not exert a deteriorative effect on sCR1 function. The 
CH50 value of sCR1 with 4.6 thiol groups per molecule was almost the same as that of 
naïve sCR1. sCR1 carrying 4.6 thiol groups was used in the following experiments.   
Maleimide groups were introduced to agarose by PMPI and sCR1-SH was covalently 
immobilized on agarose through the thiol-maleimide reaction. Microbeads made of 
agarose modified with PMPI were immersed in a sCR1-SH solution to immobilize sCR1 
to the agarose microbeads. The amount of sCR1 in the sCR1-agarose conjugates was 
determined using the micro BCA method (S–Fig. 2).  
 
3.3. Inhibitory effect of immobilized sCR1 on agarose 
Hapten-liposomes were enclosed in 2.5% sCR1-agarose mirobeads and then incubated in 
NHS to examine the inhibitory function of immobilized sCR1. When the complement 
system is activated on the hapten-liposome, the enzyme enclosed in the liposome is 
released into the solution and subsequently releases chromophore from the substrate, 
increasing the absorbance of the supernatant at 340 nm. The percentage of damaged 
liposome in NHS was evaluated from the changes in absorbance at 340 nm (Fig. 3).  



































































NHS and NHS supplemented with 50 μg/ml sCR1. Although the absorbance of the 
supernatants increased with time in all three conditions, the absorbance for sCR1-agarose 
mirobeads increased much more slowly than those without immobilized sCR1. 
Immobilized sCR1 effectively inhibited the complement activation, comparable to sCR1 
in NHS.  
 
3.4. Islet morphology 
Islets were encapsulated in microbeads made of agarose modified with PMPI. The 
microencapsulated islets were immersed in a solution of sCR1-SH immobilized to aCR1 
in the agarose microbeads. To examine the immobilization of sCR1 in agarose 
microbeads, the microbeads were immuno-stained using anti-sCR1 antibody. Clear green 
fluorescence was observed on the agarose microbeads (Fig. 4B). However, no 
fluorescence was observed for agarose not activated with PMPI. These results indicate 
that sCR1 was covalently immobilized on the agarose hydrogel through the 
thiol/maleimide reaction. 
Rat-rabbit is a discordant combination [26], as antibodies that react with rat tissue exist in 
rabbit serum. When naked rat islets are exposed to fresh rabbit serum, the antibodies form 
antigen-antibody complexes on islets and the immune complexes activate the 
complement system through the classic pathway, resulting in the destruction of islet cells. 
The protective effect of sCR1 immobilized on agarose in regards to the antibody-
complement dependent destruction of islets was examined by incubating 
microencapsulated islets in rabbit serum. Naked rat islets were rapidly destroyed over a 



































































encapsulated in sCR1-agarose microbeads (Fig. 4A). The sCR1-agarose microbeads 
effectively protected the islets. Figure 5 also includes images of islets encapsulated in 5% 
agarose microbeads without sCR1 immobilization. Although some cells located at the 
periphery were swollen, the islets kept their intact round shape even after 4 days in rabbit 
serum. Agarose microbeads alone have some protective effect against the antibody-
complement-dependent destruction of islets.  
 
3.5. Insulin release from islets 
The glucose stimulation test was carried out to determine the effects of 
microencapsulation and sCR1 immobilization on islet function (Fig. 5). The release 
insulin from islets in microbeads with or without sCR1 at high glucose concentrations 
was about 20% less than that of naked islets, with no difference observed between the 
two groups of islets in microbeads. Although the microencapsulation procedure exerted 
some deteriorative effects on islet function, islets in microbeads carrying sCR1 still 
maintained the ability to release insulin and control the amount released in response to 
the glucose concentration.  
β-cells in islets contain insulin as granules. When islets are damaged in rabbit serum, 
insulin leaks from the damaged β-cells. The amount of insulin in rabbit serum was 
determined to quantitatively evaluate islet cell death (Fig. 6). From 20 naked islets 
cultured in rabbit serum, 551.1 ng insulin leaked during the first 24 h period and 239.4 ng 
insulin leaked during the second 24 h period. After two days, the amount of insulin 
released drastically decreased because most of the β-cells were destroyed during the 



































































less than that of naked islets over the course of two days in culture. The amount of insulin 
leaked from islets in microbeads carrying sCR1 was half that leaked from islets in 
microbeads without sCR1 during. These observations indicate that the agarose hydrogel 
effectively protects islets from antibody-complement-dependent cell damage and sCR1 
immobilized on agarose exerted an additional protective effect. 
 
4. Discussion 
Our group has been examining agarose as a material to microencapsulate islets and 
demonstrated that agarose microbeads effectively protect allogeneic islets from the 
immune attack of recipient mice; thus, islet graft survival was realized without 
immunosuppressive therapy for a long period of time [3]. Though hamster islets enclosed 
in agarose microbeads cannot survive so long in recipient mice, we demonstrated that a 
combination of islet microencapsulation and B cell suppression by the administration of 
15-deoxyspergualin can realize long normoglycemia in islet xenotransplantation between 
hamster and mouse [12]. However, the administration of 15-deoxyspergualin is not a 
good choice for diabetic patients when its side effects are taken into consideration.  
In order to improve xenograft survival, some groups have examined the immobilization 
of bioactive substances to hydrogel macrocapsules [27-30]. An anti-inflammatory peptide 
was immobilized to functionalized hydrogel crosslinked by the thioester/thiol reaction 
[31]. In another study, anti-Fas mAb was conjugated to PEG hydrogel using 
photopolymerization [32]. These approaches have shown promising results for the down-
regulation of inflammatory reactions and are expected to improve graft survival. 



































































exert deteriorative effects on cell viability and protein function. In addition, the activation 
of the complement system should be controlled for the success of xenogeneic islet 
transplantation because antibody-complement-dependent cytotoxicity plays a major role 
in xenograft rejection.   
In this study, islets were enclosed in sCR1-agarose microbeads because sCR1 has the 
ability to bind complement C3b/C4b, controls the dissociation of C3 and C5 convertase, 
and also serves as a co-factor for the proteolytic cleavage of C3b/C4b by factor I. sCR1 is 
also able to inhibit complement activation in both the classical and alternative pathways, 
and it has been reported that sCR1 can prolong the survival of xenografts in a dose-
dependent manner in several animal models and pre-clinical trials [13-20]. However, 
controlling the sCR1 level in the local microenvironment of the graft is difficult with 
systemic administration of sCR1 [33]. In this study, sCR1was immobilized on agarose by 
the thiol/maleimide reaction and sCR1-agarose was used to microencapsulate islets. The 
local concentration of sCR1 surrounding the islets increased for the effective regulation 
of antibody-complement-dependent cytotoxicity. The advantage of the thiol/maleimide 
reaction is that agarose is modified with maleimide groups before microencapsulation of 
islets, and proteins carrying thiol groups can be immobilized onto the agarose microbeads 
containing living islets under physiological conditions.  
When naked rat islets were cultured in rabbit serum, large amounts of insulin leaked from 
the damaged islets over the course of a few days incubation (Fig. 6). However, no 
damaged cells were seen on the islets enclosed by sCR1-agarose microbeads (Fig. 4).  
Low levels of insulin were detected in the rabbit serum, but this was not due to leakage of 





































































Although the protective efficacy of sCR1-agarose in islet xenotransplantation should be 
carefully examined using in vivo models, the results obtained in this study suggest that it 
is a promising material to prepare a bioartificial pancreas that can be applied to islet 
xenotransplantation.   
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SCHEME AND FIGURE CAPTIONS 
 
Scheme 1. Schematic illustration of the immobilization of sCR1 on agarose. (a) Thiolation of sCR1 by 
Traut’s reagent. (b) Activation of agarose by PMPI. (c) Conjugation of sCR1-SH with the activated agarose. 
 
Fig. 1. Analysis of sCR1 isolated from CHO35.6 cell culture medium. (A) SDS-PAGE of sCR1 before and 
after purification using a heparin column. a: ASF104 medium, b: CHO culture supernatant, c: fraction from 
the culture medium collected through the heparin column. (B) CH50 values of 90% normal human serum 
supplemented with certain amounts of sCR1. (C) Inhibitory effect of sCR1 in 90% rabbit serum. 
 
Fig. 2. Effect of thiolation on sCR1 activity. CH50 values are shown for 90% normal human serum and 9 μl 
serum supplemented with 1 μl naïve sCR1 or thiolated sCR1 (0.26 μg/ml) as indicated.  
 
Fig. 3. Inhibitory effect of sCR1 on the complement-dependent lysis of hapten-liposome.  Dark circles 
indicate agarose microbeads, white circles indicate sCR1-agarose microbeads, and squares indicate 
agarose microbeads suspended in a medium supplemented with sCR1 (50 μg/ml). The average diameter of 
the agarose microbeads was 200 μm. 
 
Fig. 4. Phase contrast microscope images of microencapsulated islets (A) and Immunofluorescence staining 
of sCR1 using anti-sCR1 antibody (J3D3 primary mAb) and Alexa 488 labeled anti-mouse antibody (B). (A) 
Protection effect of sCR1-agarose microbeads. Islets were incubated in 100% normal rabbit serum for the 
indicated time  a: Islet sCR1-agarose microbeads, b: islets in agarose microbeads without sCR1, c: naked 
islets. Scale bars = 200 μm. (B) a: sCR1-agarose microbead, b: agarose microbead without sCR1. Scale 
bars = 100 μm. 
 
Fig. 5. Glucose stimulation tests of naked islets and microencapsulated islets (MIs) with or without sCR1. 
 
Fig. 6. The amount of insulin release was determined to measure β-cell lysis during islet incubation in rabbit 
serum for 4 days.  : Naked islets,  : Islets in agarose microbeads without sCR1,  : Islets in sCR1-
agarose microbeads.  
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MEM Alpha (α-MEM) medium, RPMI-1640 medium, Hanks’ balanced salt solution 
(HBSS), penicillin, and streptomycin were purchased from Invitrogen (Carlsbad, CA, 
USA). Fetal bovine serum (FBS) was purchased from Equitech-Bio (Kerrville, TX, 
USA), ASF 104 medium from Ajinomoto (Tokyo, Japan), phosphate-buffered saline 
(PBS) from Nissui Pharmaceutical (Tokyo, Japan), methotrexate from Sigma-Aldrich (St. 
Louis, MO, USA), and the micro BCA protein concentration kit from Thermo Fisher 
Scientific (Rockford, IL., USA). 5, 5’-Dithiobis (2-nitrobenzoic acid, Ellman’s reagent), 
DMSO, and acetone were purchased from Nacalai Tesque (Kyoto, Japan). Ficoll was 
purchased from GE Healthcare Bio-Sciences AB (Uppsala, Sweden), Conray from Daichi 
Sankyo (Tokyo, Japan), EDTA from Dojindo (Kumamoto, Japan), Nembutal 
(pentobarbital) from Dainippon Sumitomo (Osaka, Japan), and cysteine from ICN 
Biomedical (Ohio, USA). Heparin sepharose 6B and sephadex G25 columns were 
purchased from GE Healthcare (Buckinghamshire, UK). SDS-PAGE materials were 
purchased from NAG Research Laboratories.  
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S1. Immobilization of sCR1 on agarose hydrogel 
Thiol groups were introduced to sCR1 by converting amino groups with Traut’s reagent.  
Because sCR1 has 74 lysine residues, a number of amino groups are converted to thiol 
groups. The number of introduced thiol groups was plotted against the molar ratio of 
Traut’s reagent to sCR1 (S-Fig. 1). Although the number of thiol groups introduced on 
sCR1 increased with increasing Traut’s reagent concentration, a few thiol groups were 
introduced even at higher molar ratios of Traut’s reagent to sCR1.  
Maleimide groups were introduced to agarose by PMPI. The sCR1-SH carrying 4.6 thiol 
groups was covalently immobilized on agarose through the thiol-maleimide reaction. The 
amount of immobilized sCR1 on agarose was plotted against the molar ratio of PMPI to 
agarose (S-Fig. 2). The amount of immobilized sCR1 increased with an increasing 
amount of PMPI used to modify the agarose, suggesting that sCR1 was immobilized 
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S-Fig. 1. Number of thiol groups introduced per sCR1 molecule compared to the molar 
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S-Fig. 2. Amount of immobilized sCR1 on agarose activated with varying amounts of 
PMPI. sCR1-SH carrying 4.6 thiol groups/sCR1 was used.  
 
 
 
 
 
 
